A phase I dose escalation study of ARQ 171 in adult patients with advanced solid tumors

Trial Profile

A phase I dose escalation study of ARQ 171 in adult patients with advanced solid tumors

Discontinued
Phase of Trial: Phase I

Latest Information Update: 08 Mar 2017

At a glance

  • Drugs ARQ 171 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors ArQule
  • Most Recent Events

    • 12 May 2008 Status changed from suspended to discontinued as ArQule state they will no longer pursue clinical testing of ARQ 171.
    • 20 Mar 2008 Status changed from recruiting to suspended, in accordance with clinicaltrials.gov.
    • 26 Nov 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top